GlobeNewswire Inc | Mar 3, 2021 12:00PM EST

March 03, 2021

Sanofis Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members

Paris, France March 3, 2021 At its meeting on March 3, 2021, Sanofis Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on April 30, 2021, the appointment of two new Directors, Christian Brandts and Barbara Lavernos, as well as the ratification of appointment by cooptation of Gilles Schnepp and the renewal of the mandates of Fabienne Lecorvaisier and Melanie Lee. Bernard Charls, whose term of office will expire at the end of the next General Shareholder Meeting, did not wish to stand for re-election in order to avoid conflicts of interest that could arise from the development of the partnership between Sanofi and Dassault SYSTEMES, which he manages. will not be renewed upon his own request. Moreover, Laurent Attal, after serving on the Board of Directors for 9 years, has declared his intention to retire and as a result to resign from his mandate as a Board Member before that General Meeting.

Christian Brandts is currently Director at the University Cancer Center Frankfurt. In addition to his duties, Christian Brandts is pursuing his research activities focused mainly on translational cancer research and personalized oncology. He is part of several national and international networks of oncology experts and is a member of the Board of the Organisation of European Cancer Institutes (OECI).

Christian Brandts is a graduate from the Medical School of the Free University of Berlin, and then specialized in Internal Medicine and Hematology / Oncology at the Charit University Hospital in Berlin and the University Hospital in Mnster.

Barbara Lavernos took over in February 2021 as President Research, Innovation and Technologies of the L'Oral Group, having spent her entire career at l'Oral, which she joined in 1991. In 2004, she was appointed Global Chief Procurement Officer for all global purchases at L'Oral, and in 2012, General Manager for Travel Retail department. In 2014, she was appointed Chief Operating Officer and member of the Groups Executive Committee, and she has led from the end of 2018 all the IT teams with the groups technological transformation as her mission.

Barbara Lavernos graduated from Ecole des Hautes Etudes dIngnieur en gnie chimique (School of Advanced Studies in Chemical Engineering - HEI).

The arrivals of Christian Brandts and Barbara Lavernos will strengthen the Board of Directors expertise in technology and science, notably in the field of oncology. The Board of Directors thus continues to diversify its profiles and competencies, in line with its roadmap, said Serge Weinberg, Chairman of the Board of Directors.

The composition of the Boards specialized committees will be reviewed following the Annual General Meeting of Shareholders scheduled for April 30, 2021.



About Sanofi

Sanofi is dedicated to supporting people through their health challenges. Weare a global biopharmaceutical company focused on human health. We preventillness with vaccines, provide innovative treatments to fight pain and easesuffering. We stand by the few who suffer from rare diseases and the millionswith long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transformingscientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life



Investor Relations Contacts Paris Eva Schaefer-Jansen Arnaud DelepineMedia Relations Contacts Yvonne NaughtonSandrine GuendoulTel.: +33 (0)1 53 77 46 46 MR@sanofi.com Investor Relations Contacts North America Felix Lauscher Fara BerkowitzAshleigh Koss Suzanne GrecoTel.: +1 (908) 205-2572Ashleigh.Koss@sanofi.com

IR main line: Tel.: +33 (0)1 53 77 45 45 investor.relations@sanofi.com



https://www.sanofi.com/en/investors/contact



Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in thePrivate Securities Litigation Reform Act of 1995, as amended. Forward-lookingstatements are statements that are not historical facts. These statementsinclude projections and estimates and their underlying assumptions, statementsregarding plans, objectives, intentions and expectations with respect to futurefinancial results, events, operations, services, product development andpotential, and statements regarding future performance. Forward-lookingstatements are generally identified by the words ?expects?, ?anticipates?,?believes?, ?intends?, ?estimates?, ?plans? and similar expressions. AlthoughSanofi?s management believes that the expectations reflected in suchforward-looking statements are reasonable, investors are cautioned thatforward-looking information and statements are subject to various risks anduncertainties, many of which are difficult to predict and generally beyond thecontrol of Sanofi, that could cause actual results and developments to differmaterially from those expressed in, or implied or projected by, theforward-looking information and statements. These risks and uncertaintiesinclude among other things, the uncertainties inherent in research anddevelopment, future clinical data and analysis, including post marketing,decisions by regulatory authorities, such as the FDA or the EMA, regardingwhether and when to approve any drug, device or biological application that maybe filed for any such product candidates as well as their decisions regardinglabelling and other matters that could affect the availability or commercialpotential of such product candidates, the fact that product candidates ifapproved may not be commercially successful, the future approval and commercialsuccess of therapeutic alternatives, Sanofi?s ability to benefit from externalgrowth opportunities, to complete related transactions and/or obtain regulatoryclearances, risks associated with intellectual property and any related pendingor future litigation and the ultimate outcome of such litigation, trends inexchange rates and prevailing interest rates, volatile economic and marketconditions, cost containment initiatives and subsequent changes thereto, andthe impact that COVID-19 will have on us, our customers, suppliers, vendors,and other business partners, and the financial condition of any one of them, aswell as on our employees and on the global economy as a whole. Any materialeffect of COVID-19 on any of the foregoing could also adversely impact us.This situation is changing rapidly and additional impacts may arise of which weare not currently aware and may exacerbate other previously identified risks.The risks and uncertainties also include the uncertainties discussed oridentified in the public filings with the SEC and the AMF made by Sanofi,including those listed under ?Risk Factors? and ?Cautionary Statement RegardingForward-Looking Statements? in Sanofi?s annual report on Form 20-F for the yearended December 31, 2019. Other than as required by applicable law, Sanofi doesnot undertake any obligation to update or revise any forward-lookinginformation or statements.







Attachment

-- Press Release